Order Article Reprints

Patnaik A, Hamilton E, Xing Y, Rasco DW, Smith L, Lee Y-L, Fang S, Wei J, Hui A-M. A Phase I Dose-Escalation and Dose-Expansion Study of FCN-437c, a Novel CDK4/6 Inhibitor, in Patients with Advanced Solid Tumors. Cancers. 2022; 14(20):4996. https://doi.org/10.3390/cancers14204996

Patnaik, Amita, Erika Hamilton, Yan Xing, Drew W. Rasco, Lon Smith, Ya-Li Lee, Steven Fang, Jiao Wei, and Ai-Min Hui. 2022. "A Phase I Dose-Escalation and Dose-Expansion Study of FCN-437c, a Novel CDK4/6 Inhibitor, in Patients with Advanced Solid Tumors" Cancers 14, no. 20: 4996. https://doi.org/10.3390/cancers14204996

Patnaik, A., Hamilton, E., Xing, Y., Rasco, D. W., Smith, L., Lee, Y. -L., Fang, S., Wei, J., & Hui, A. -M. (2022). A Phase I Dose-Escalation and Dose-Expansion Study of FCN-437c, a Novel CDK4/6 Inhibitor, in Patients with Advanced Solid Tumors. Cancers, 14(20), 4996. https://doi.org/10.3390/cancers14204996